Clinical Trials Directory

Trials / Terminated

TerminatedNCT02795520

Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia

Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
32 (actual)
Sponsor
OncoTherapy Science, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this study OTS167 will be administrated to patients with AML, ALL, advanced MDSs, advanced MPNs, or advanced CML.

Conditions

Interventions

TypeNameDescription
DRUGOTS167IV

Timeline

Start date
2016-04-01
Primary completion
2021-05-01
Completion
2021-09-01
First posted
2016-06-10
Last updated
2021-11-24

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02795520. Inclusion in this directory is not an endorsement.